Nationwide survey on current treatments for IgA nephropathy in Japan

Clinical and Experimental Nephrology

Volumn 17, Issue 6, 2013, Pages 827-833

  Matsuzaki, Keiichi ^a,e   Suzuki, Yusuke ^a,e   Nakata, Junichiro ^a,e   Sakamoto, Naoko ^b,e   Horikoshi, Satoshi ^a,e   Kawamura, Tetsuya ^c,e   Matsuo, Seiichi ^d,e   Tomino, Yasuhiko ^a,e  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Ministry of Health Labour and Welfare   (Japan)

Author keywords

IgA nephropathy; Nationwide survey; Questionnaire survey; Tonsillectomy and steroid pulse therapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; COLECALCIFEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FARNOQUINONE; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; METHYLPREDNISOLONE; PREDNISOLONE; PROTON PUMP INHIBITOR; STEROID; WARFARIN;

ARTICLE; BLOOD EXAMINATION; BLOOD PRESSURE MONITORING; BONE DENSITOMETRY; CATARACT; CLINICAL PROTOCOL; CORTICOSTEROID INDUCED OSTEOPOROSIS; COUGHING; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG DOSE REDUCTION; GASTROINTESTINAL ENDOSCOPY; HEALTH SURVEY; HEMATURIA; HUMAN; HYPERKALEMIA; HYPOTENSION; IMMUNOGLOBULIN A NEPHROPATHY; INTERNAL MEDICINE; JAPAN; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; MONOTHERAPY; MOON FACE; PRESCRIPTION; PROTEINURIA; PSYCHOSIS; QUESTIONNAIRE; REMISSION; STEROID THERAPY; TEACHING HOSPITAL; THERAPY; TONSILLECTOMY; UNSPECIFIED SIDE EFFECT;

ADULT; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AZATHIOPRINE; CHILD; COMBINED MODALITY THERAPY; GLOMERULONEPHRITIS, IGA; HEPARIN; HUMANS; JAPAN; PLATELET AGGREGATION INHIBITORS; PREDNISOLONE; PROTEINURIA; QUESTIONNAIRES; RENIN-ANGIOTENSIN SYSTEM; TONSILLECTOMY; WARFARIN;

EID: 84891484034     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-013-0779-7     Document Type: Article

References (36)

1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;245:709-27.
2. Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med. 1990;89:209-15.
3. Li L-S, Liu Z-H. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004;66:920-3.
4. Simon P, Ramee MP, Boulahrouz R, Stanescu C, Charasse C, Ang KS, et al. Epidemiologic data of primary glomerular diseases in western France. Kidney Int. 2004;66:905-8.
5. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005;16:2088-97.
6. D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004;24:179-96.
7. Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int. 2006;69:1934-8.
8. Progressive Renal Diseases Research, Research on intractable disease, from the Ministry of Health Labors and Welfare of Japan. Clinical guides for Immunoglobulin A (IgA) nephropathy in Japan, third version. Nihon Jinzo Gakkai shi 2011; 53:123-35.
9. Kobayashi Y, Fujii K, Hiki Y, Tateno S. Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases. Q J Med. 1986;61:935-43.
10. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883-7.
11. Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736-43.
12. Sato M, Hotta O, Tomioka S, Chiba S, Miyazaki M, Noshiro H, et al. Cohort study of advanced IgA nephropathy: efficacy and limitations of corticosteroids with tonsillectomy. Nephron Clin Pract. 2003;93:c137-45.
13. Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301-7.
14. Kawaguchi T, Ieiri N, Yamazaki S, Hayashino Y, Gillespie B, Miyazaki M, et al. Clinical effectiveness of steroid pulse therapy combined with tonsillectomy in patients with immunoglobulin A nephropathy presenting glomerular haematuria and minimal proteinuria. Nephrology. 2010;15:116-23.
15. Miura N, Imai H, Kikuchi S, Hayashi S, Endoh M, Kawamura T, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460-6.
16. Yoshikawa N, Igarashi T, Ishikura K, Kaku Y, Nakazato H, Kamei K, et al. Guidelines for the treatment of childhood IgA nephropathy. Nihon Jinzo Gakkai shi. 2008;50:31-41.
17. Yoshikawa N, Ito H, Sakai T. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol. 1999;10:101-9.
18. Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol. 2006;1:511-7.
19. Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, et al. Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study. Pediatr Nephrol. 2008;23:757-63.
20. Pozzi C, Andrulli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol. 2010;21:1783-90.
21. Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K, et al. Long term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol. 2011;6:1301-7.
22. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology (Carlton). 2004;9:177-85.
23. Barratt J, Feehally J, Lai KN (ed): Recent Advances in IgA Nephropathy. 1st ed. World Scientific Pub Co Inc; 2009: Chapter 24 "Other non-immunomodulatory agents".
24. Chan MK, Kwan SY, Chan KW, Yeung CK. Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis. Am J Kidney Dis. 1987;9:417-21.
25. Lee GS, Choong HL, Chiang GSC, Woo KT. Three year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment. Nephrology (Carlton). 1997;3:117-21.
26. Tomino Y. Long term effects of dilazep hydrochloride, an anti-platelet drug, on patients with IgA nephropathy - reports of 5-year treatment. Curr. Top. Pharmacol. 2007;11:45-9.
27. Taji Y, Kuwahara T, Shikata S, Morimoto T. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin Exp Nephrol. 2006;10:268-73.
28. Floege J, Eitner F. Current therapy for IgA nephropathy. J Am Soc Nephrol. 2011;22:1785-94.
29. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2:139-274.
30. Suzuki Y, Thang NT, Horikoshi S, Shirato I, Nakamura S, Kimura M, et al. Effect of valsartan, an angiotensin II AT 1 receptor blocker, on the glomerular fibrosis of IgA nephropathy in ddY mice. Nephron. 2000;86:374-5.
31. Li PK-T, Leung CB, Chow KM, Cheng YL, Fung SK-S, Mak SK, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751-60.
32. Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18:1880-8.
33. Praga M, Gutiérrez E, González E, Morales E, Hernández E. Treatment of IgA nephropathy with ACE Inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14:1578-83.
34. Tomino Y, Kawamura T, Kimura K, Endoh M, Hosoya T, Horikoshi S, et al. Antiproteinuric effect of olmesartan in patients with IgA nephropathy. J Nephrol. 2009;2:224-31.
35. Moriyama T, Amamiya N, Ochi A, Tsuruta Y, Shimizu A, Kojima C, et al. Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function. Clin Exp Nephrol. 2011;15:700-7.
36. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38:18-25.